We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+1.16%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$167M
AUM Growth
-$2.8M
Cap. Flow
+$3.4M
Cap. Flow %
2.04%
Top 10 Hldgs %
73.09%
Holding
35
New
13
Increased
8
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
VNDA icon
Vanda Pharmaceuticals
VNDA
+$8.68M
2
BSTC
BioSpecifics Technologies Corp.
BSTC
+$7.85M
3
VCYT icon
Veracyte
VCYT
+$6.73M
4
CDNA icon
CareDx
CDNA
+$5.74M
5
VYNT
Vyant Bio, Inc. Common Stock
VYNT
+$4.54M

Top Sells

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$14.1M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$10.3M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$8.59M
4
VCEL icon
Vericel Corp
VCEL
+$5.85M
5
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$3.71M

Sector Composition

Rank Sector Weight
1 Healthcare 98.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
26
Amarin Corp
AMRN
$286M
$70K 0.04%
+877
New +$60.4K
AVDL
27
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-985,210
Closed -$10.3M
PCRX icon
28
Pacira BioSciences
PCRX
$1B
– –
-375,200
Closed -$14.1M
TRIB
29
Trinity Biotech
TRIB
$6.66M
– –
-24,534
Closed -$688K
VCEL icon
30
Vericel Corp
VCEL
$2.35B
– –
-975,711
Closed -$5.85M
ICPT
31
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-18,600
Closed -$1.08M
OXFD
32
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-162,286
Closed -$2.73M
CASM
33
DELISTED
CAS Medical Systems, Inc.
CASM
– –
-812,718
Closed -$748K
CBMX
34
DELISTED
CombiMatrix Corporation
CBMX
– –
-63,283
Closed -$475K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Stonepine Capital Management held 35 positions worth $167M, down 1.7% from $170M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Stonepine Capital Management's Q4 2017 filing shows 13 new, 8 increased, 5 reduced and 8 closed positions. Its largest new stake was CareDx: 920,000 shares worth $6.75M. The largest sale was Pacira BioSciences, an estimated $14.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

  • Stonepine Capital Management's largest Q4 2017 buy was CareDx: 920,000 shares worth $6.75M.
  • Stonepine Capital Management added most to Vanda Pharmaceuticals in Q4 2017, an estimated $8.68M increase.
  • Stonepine Capital Management's biggest Q4 2017 reduction was Enanta Pharmaceuticals, cutting an estimated $8.59M.
  • Stonepine Capital Management fully exited Pacira BioSciences in Q4 2017, selling an estimated $14.1M.
  • Stonepine Capital Management's ten largest holdings make up 73% of its $167M portfolio in Q4 2017.
  • Stonepine Capital Management opened 13 new positions and closed 8 in Q4 2017.
  • Stonepine Capital Management's portfolio value fell 1.7% quarter-over-quarter to $167M.

Based on Stonepine Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.